100% efficacy to ombitasvir/paritaprevir/ritonavir (± dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patients

被引：0
|
作者：
Sanai, F. M. [1 ,2 ]
Alghamdi, A. S. [3 ]
Afghani, A. [4 ]
Alswat, K. A. [5 ]
Aseeri, A. [6 ]
Babatin, M. A. [3 ]
机构：
[1] King Abdul Aziz Med City, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[2] King Saud Univ, Liver Dis Res Ctr, Riyadh, Saudi Arabia
[3] King Fahad Hosp, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[4] King Fahad Hosp, Dept Med, Gastroenterol Unit, Madinah Al Munawarrah, Saudi Arabia
[5] King Saud Univ, Liver Dis Res Ctr, Dept Med, Gastroenterol Unit, Riyadh, Saudi Arabia
[6] King Fahd Med City, Riyadh, Saudi Arabia
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30944-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-277
引用
收藏
页码：S312 / S312
页数：1
相关论文
共 50 条
  • [1] Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4
    Abad, Soraya
    Vega, Almudena
    Hernandez, Eduardo
    Merida, Evangelina
    de Sequera, Patricia
    Albalate, Marta
    Macias, Nicolas
    Milla, Monica
    Lopez-Gomez, Juan M.
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 45 (03) : 267 - 272
  • [2] Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir Plus Ribavirin in Daily Practice Hepatitis C Virus Genotype 1-or 4-Infected Patients with Compensated Cirrhosis
    Petta, Salvatore
    Marzioni, Marco
    Russo, Pierluigi
    Aghemo, Alessio
    Alberti, Alfredo
    Ascione, Antonio
    Antinori, Andrea
    Bruno, Raffaele
    Bruno, Savino
    Chirianni, Antonio
    Gaeta, Giovanni B.
    Giannini, Edoardo G.
    Merli, Manuela
    Messina, Vincenzo
    Montilla, Simona
    Perno, Carlo F.
    Puoti, Massimo
    Raimondo, Giovanni
    Rendina, Maria
    Ceccherini-Silberstein, Francesca
    Villa, Erica
    Zignego, Anna Linda
    Pani, Luca
    Craxi, Antonio
    HEPATOLOGY, 2016, 64 : 448A - 448A
  • [3] Ombitasvir/paritaprevir/ritonavir + dasabuvir +/-ribavirin in real world hepatitis C patients
    Nicole Loo
    Eric Lawitz
    Naim Alkhouri
    Jennifer Wells
    Carmen Landaverde
    Angie Coste
    Rossalynn Salcido
    Michael Scott
    Fred Poordad
    World Journal of Gastroenterology, 2019, (18) : 2229 - 2239
  • [4] Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1-infected patients with compensated cirrhosis and multiple comorbidities
    Popa, R. C.
    Mihai, C.
    Trifan, A.
    Stanciu, C.
    Gheorghe, L.
    Iacob, S.
    Arama, V.
    Rogoveanu, I.
    Diculescu, M.
    Goldis, A.
    Bataga, S.
    Seicean, A.
    Sandulescu, L.
    Nastase, R.
    Molagic, V.
    Brisc, C.
    Curescu, M.
    Prelipcean, C. C.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S732 - S732
  • [5] Efficacy and Safety of the Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir Regimen for Chronic Hepatitis C in Hemodialysis Patients
    Tosun, Guven Gurkan
    Sultanova, Fidan
    Nihan, A. K.
    Hizel, Kenan
    MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2019, 8
  • [6] Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
    Bernstein, David E.
    Tran, Albert
    Martin, Paul
    Kowdley, Kris V.
    Bourliere, Marc
    Sulkowski, Mark S.
    Pockros, Paul J.
    Renjifo, Boris
    Wang, Deli
    Shuster, Diana L.
    Cohen, Daniel E.
    Jacobson, Ira M.
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (02): : 245 - 256
  • [7] ZIRCON: pharmacokinetics, safety, and efficacy of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in adolescents with genotype 1 or 4 hepatitis C virus infection
    Leung, D. H.
    Yao, B.
    Viani, R. M.
    Gonzalez-Peralta, R. P.
    Jonas, M. M.
    Lobritto, S. J.
    Narkewicz, M. R.
    Sokal, E.
    Fortuny, C.
    Hsu, E.
    Wirth, S.
    Del Valle-Segarra, A.
    Zha, J.
    Larsen, L.
    Liu, L.
    Shuster, D. L.
    Cohen, D. E.
    Rosenthal, P.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S300 - S301
  • [8] High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease
    Sanai, Faisal M.
    Alghamdi, Abdullah S.
    Afghani, Ahmad A.
    Alswat, Khalid
    AlZanbagi, Adnan
    Alghamdi, Mosfer N.
    AlMousa, Abdallah
    Aseeri, Mohammed
    Assiri, Abdullah M.
    Babatin, Mohamed A.
    LIVER INTERNATIONAL, 2018, 38 (08) : 1395 - 1401
  • [9] Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4
    Leung, Daniel H.
    Wirth, Stefan
    Yao, Betty B.
    Viani, Rolando M.
    Gonzalez-Peralta, Regino P.
    Jonas, Maureen M.
    Lobritto, Steven J.
    Narkewicz, Michael R.
    Soka, Etienne
    Fortuny, Claudia
    Hsu, Evelyn K.
    Del Valle-Segarra, Antonio
    Zha, Jiuhong
    Larsen, Lois
    Liu, Li
    Shuster, Diana L.
    Cohen, Daniel E.
    Rosenthall, Philip
    HEPATOLOGY COMMUNICATIONS, 2018, 2 (11) : 1311 - 1319
  • [10] Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia
    Shafie, Asrul Akmal
    Abu Hassan, Muhammad Radzi
    Ong, Siew Chin
    Virabhak, Suchin
    Gonzalez, Yuri Sanchez
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 164 - 171
12345